ORBIMED ADVISORS LLC
Q3 2022 13F-HR Holdings
Net value change ($000)
-131,815
(-2.4%)
New positions
13
Sold out positions
21
Turnover %
16.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Third Harmonic Bio, Inc. | 109,629 | NEW |
| SRPT | 100,032 | 6673.2% |
| ALNY | 50,140 | NEW |
| TMO | 40,946 | 66.5% |
| BIIB | 37,208 | 163.5% |
| BELLUS Health Inc. | 35,580 | 265.7% |
| TERN | 34,662 | 368.7% |
| VRNA | 34,340 | 143.9% |
| EWTX | 31,243 | 27.9% |
| Mirati Therapeutics, Inc. | 25,896 | 35.4% |
Top Reduces (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | -168,178 | -100.0% |
| Turning Point Therapeutics, Inc. | -151,422 | -100.0% |
| Sierra Oncology, Inc. | -108,043 | -100.0% |
| Biohaven Pharmaceutical Holding Co Ltd. | -78,955 | -75.4% |
| Global Blood Therapeutics, Inc. | -65,306 | -100.0% |
| ARQT | -48,389 | -47.5% |
| ABBV | -41,971 | -34.3% |
| PFE | -30,136 | -20.9% |
| Gracell Biotechnologies Inc. | -17,978 | -41.5% |
| GILD | -17,777 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
14,271
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|